Floatz logo

Belzutifan

Hemangioblastoma (HB) of the Central Nervous System (CNS)

José Claudio Casali da RochaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hemangioblastoma (HB) of the Central Nervous System (CNS) cohort.

Asset / SponsorPhaseRating
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC

Same molecule, other indications

Belzutifan is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Von Hippel Lindau DiseaseDormant
BB
Indicative ·
66 / 100
View asset →
von Hippel-Lindau diseaseDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →